Company
Akeso
Akeso has 30 drugs tracked on RxWires: 8 in Phase 3, 6 in Phase 2, 9 in Phase 1/2, 6 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| AK112, Carboplatin, Paxlitaxel | Phase 3 | Advanced Squamous Non Small Cell Lung Cancer |
| AK111 | Phase 3 | Ankylosing Spondylitis |
| AK104 | Phase 3 | Cervical Cancer |
| AK101 | Phase 3 | Psoriasis Vulgaris |
| AK102 | Phase 3 | Hyperlipidemia |
| AK105 | Phase 3 | Lung Cancer Non-small Cell Stage IV |
| Cadonilimab | Phase 3 | Gastric / Gastroesophageal Junction Adenocarcinoma |
| Ivonescimab, docetaxel | Phase 3 | Non-Small Cell Lung Cancer |
| AK112+oxaliplatin+capecitabine | Phase 2 | Gastric or Gastroesophageal Junction Adenocarcinoma |
| AK139 | Phase 2 | Moderate-to-Severe Atopic Dermatitis |
| Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil | Phase 2 | The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC |
| AK120 | Phase 2 | Atopic Dermatitis |
| AK146D1 for injection | Phase 2 | Advanced Non Small Cell Lung Cancer (NSCLC) |
| Cardunolizumab | Phase 2 | Vulvar and Vaginal Cancer |
| AK109+AK104 | Phase 1/2 | Advanced Solid Tumor |
| AK104+anlotinib | Phase 1/2 | NSCLC |
| AK117 | Phase 1/2 | Acute Myeloid Leukemia |
| AK112 low dose | Phase 1/2 | Ovarian Neoplasms |
| Ivonescimab Combined With Chemotherapy | Phase 1/2 | Malignant Pleural Mesothelioma, Advanced |
| Drug: AK129 Drug：oxaliplatin Drug：capecitabine | Phase 1/2 | Gastric Adenocarcinoma |
| AK129 | Phase 1/2 | Classic Hodgkin Lymphoma |
| AK138D1 | Phase 1/2 | Non-Small Cell Lung Cancer |
| AK119 | Phase 1/2 | Colorectal Cancer |
| AK-105 | Phase 1 | Advanced Cancer |
| AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion | Phase 1 | Advanced Malignant Tumors |
| AK129 IV infusion | Phase 1 | Advanced Malignant Tumors(Stage IA-IB) |
| AK-104 | Phase 1 | Advanced Cancer |
| AK157D1 for injection | Phase 1 | Advanced Solid Tumors |
| AK150 | Phase 1 | Advanced Malignant Solid Tumors |
| albendazole | Not Applicable | Hookworm Stool Burden |
Latest
Follow Akeso on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.